Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL16829697

O=S(=O)([O-])C(F)(F)F.[Cu+].[Cu+].[I-]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Trifluoromethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 2/20 0.32
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
GPR3 P46089 2/20 0.41
KCNH2 Q12809 6/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL6478953 0.96 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL164548 0.96
Trifluoromethanesulfonic Acid SCHEMBL8214511 0.92 CA1 (0.41) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL25285896 0.88 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL25292546 0.88 GPR3 (0.48) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL25301943 0.88 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL23430060 0.88 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL20570425 0.88
Trifluoromethanesulfonic Acid SCHEMBL1136415 0.88 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL25255863 0.88 CA1 (0.44) CA1CA2CA7CA13GPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3082786-B1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME (US) 2021-10-27 EP disclosed
US-9834563-B2 Antidiabetic substituted heteroaryl compounds MERCK SHARP & DOHME CORP. (US) 2017-12-05 US disclosed
US-20170166578-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME LLC 2017-06-15 US disclosed
EP-3082786-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS Merck Sharp & Dohme Corp. (US) 2016-10-26 EP disclosed
WO-2015095256-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed
WO-2015089809-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166578-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS GPR119, GPR65, GPR55 ACHE 3870/4885CA1 4839/4885CA2 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.